Can vitamin a derivative shield immune system during cancer radiation?

NCT ID NCT06439888

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding a drug called ATRA (a form of vitamin A) to standard radiation therapy can prevent a drop in infection-fighting white blood cells in people with a few metastatic tumors. About 58 adults with solid cancers that have spread to up to 5 spots will receive radiation to all visible tumors, with or without ATRA pills taken for 3 days every 3 weeks. The goal is to see if the combination is safe and reduces the risk of low lymphocyte counts, which can weaken the immune system.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
all-trans retinoic acid (ATRA, also known as tretinoin) plus stereotactic body radiation therapy (SBRT)
What this could lead to
If successful, this approach could reduce a common side effect of radiation (low white blood cell counts) and potentially improve cancer control in patients with a few metastatic spots.
What could go wrong
This is an early-phase trial with only 58 participants, so results may not apply broadly. ATRA can cause side effects like skin dryness or headache, and the combination may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Léon Bérard

    NOT_YET_RECRUITING

    Lyon, 69000, France

  • Gustave Roussy

    RECRUITING

    Villejuif, 94800, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.